ImmunityBio, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $113.3M | $14.7M | $622,000 | $240,000 | $934,000 |
| Cost of revenue | $753,000 | $0 | $0 | $0 | — |
| Selling, general & administrative | — | $168.8M | $129.6M | $102.7M | $135.3M |
| Research and development | — | $190.1M | $232.4M | $248.1M | $196.0M |
| Operating expenses | — | $358.9M | $362.9M | $351.5M | $331.2M |
| Operating income | -$256.0M | -$344.2M | -$362.2M | -$351.3M | -$330.3M |
| Interest expense | $60.9M | $114.6M | $128.8M | $63.5M | $14.8M |
| Pretax income | -$351.6M | -$413.6M | -$583.9M | -$417.3M | -$349.8M |
| Income tax expense | -$135,000 | $0 | -$40,000 | $34,000 | $9,000 |
| Net income | -$351.4M | -$413.6M | -$583.2M | -$416.6M | -$346.8M |
| Balance Sheet | |||||
| Cash and equivalents | $88.3M | $143.4M | $265.5M | $104.6M | $181.1M |
| Current assets | $314.9M | $184.6M | $294.1M | $140.6M | $334.3M |
| Total assets | $501.9M | $382.9M | $504.5M | $362.4M | $468.9M |
| Current liabilities | $61.8M | $54.9M | $58.3M | $500.9M | $369.0M |
| Total liabilities | $1.0B | $871.1M | $1.1B | $812.2M | $712.8M |
| Stockholders' equity | -$500.5M | -$489.1M | -$587.0M | -$447.3M | -$242.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$304.9M | -$391.2M | -$366.8M | -$337.5M | -$274.4M |
| Depreciation and amortization | $15.5M | $17.6M | $18.5M | $18.3M | $14.2M |
| Stock-based compensation | $36.8M | $34.4M | $49.2M | $40.2M | $57.2M |
| Capital expenditure | $3.8M | $6.9M | $30.6M | $78.2M | $33.6M |
| Free cash flow | -$308.8M | -$398.1M | -$397.3M | -$415.7M | -$308.0M |
| Share repurchases | — | — | — | — | $0 |
| Impairments | $14.0M | $0 | $0 | $1.3M | $0 |
Shares outstanding 1.0B · Free float 66.8%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.